152 related articles for article (PubMed ID: 38664331)
1. Utility of Initial Tumor Reduction as a Prognostic Factor in Esophageal Squamous Cell Cancer Patients Undergoing Neoadjuvant Chemotherapy Followed by Surgery : A Retrospective Cohort Study.
Hagi T; Shiraishi O; Nakanishi T; Kohda M; Hiraki Y; Kato H; Yasuda A; Shinkai M; Imano M; Yasuda T
Ann Surg Oncol; 2024 Apr; ():. PubMed ID: 38664331
[TBL] [Abstract][Full Text] [Related]
2. Significance of lymphovascular invasion in esophageal squamous cell carcinoma undergoing neoadjuvant chemotherapy followed by esophagectomy.
Oguma J; Ishiyama K; Kurita D; Kanematsu K; Kubo K; Utsunomiya D; Yamamoto S; Honma Y; Kato K; Daiko H
Esophagus; 2023 Apr; 20(2):215-224. PubMed ID: 36565340
[TBL] [Abstract][Full Text] [Related]
3. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
4. Multicenter randomized phase II study of cisplatin and fluorouracil plus docetaxel (DCF) compared with cisplatin and fluorouracil plus Adriamycin (ACF) as preoperative chemotherapy for resectable esophageal squamous cell carcinoma (OGSG1003).
Yamasaki M; Yasuda T; Yano M; Hirao M; Kobayashi K; Fujitani K; Tamura S; Kimura Y; Miyata H; Motoori M; Shiraishi O; Makino T; Satoh T; Mori M; Doki Y
Ann Oncol; 2017 Jan; 28(1):116-120. PubMed ID: 27687307
[TBL] [Abstract][Full Text] [Related]
5. Neoadjuvant chemotherapy of triplet regimens of docetaxel/cisplatin/5-FU (DCF NAC) may improve patient prognosis of cStage II/III esophageal squamous cell carcinoma-propensity score analysis.
Yamashita K; Katada N; Moriya H; Hosoda K; Mieno H; Katada C; Koizumi W; Hoshi K; Watanabe M
Gen Thorac Cardiovasc Surg; 2016 Apr; 64(4):209-15. PubMed ID: 26868531
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Factors for Esophageal Squamous Cell Carcinoma Treated with Neoadjuvant Docetaxel/Cisplatin/5-Fluorouracil Followed by Surgery.
Sugimura K; Miyata H; Shinno N; Ushigome H; Asukai K; Yanagimoto Y; Hasegawa S; Takahashi Y; Yamada D; Yamamoto K; Nishimura J; Motoori M; Wada H; Takahashi H; Yasui M; Omori T; Ohue M; Yano M
Oncology; 2019; 97(6):348-355. PubMed ID: 31461716
[TBL] [Abstract][Full Text] [Related]
7. Prognosis of patients with residual pathological disease after neoadjuvant docetaxel, cisplatin, and 5-fluorouracil therapy and surgery for esophageal squamous cell carcinoma: a retrospective cohort study.
Okunaka M; Kotani D; Fujiwara H; Sato K; Fujiwara N; Mishima S; Sakashita S; Yoshino T; Fujita T; Kojima T
Ther Adv Med Oncol; 2024; 16():17588359241229432. PubMed ID: 38405034
[TBL] [Abstract][Full Text] [Related]
8. Three-Course Neoadjuvant Chemotherapy Associated with Unfavorable Survival of Non-responders to the First Two Courses for Locally Advanced Esophageal Cancer.
Kubo Y; Makino T; Yamasaki M; Tanaka K; Yamashita K; Shiraishi O; Sugimura K; Miyata H; Motoori M; Fujitani K; Takeno A; Hirao M; Kimura Y; Satoh T; Yano M; Eguchi H; Yasuda T; Doki Y
Ann Surg Oncol; 2023 Sep; 30(9):5899-5907. PubMed ID: 37316744
[TBL] [Abstract][Full Text] [Related]
9. Impact of Relative Dose Intensity of Docetaxel, Cisplatin, and 5-Fluorouracil Neoadjuvant Chemotherapy on Survival of Esophageal Squamous Cell Cancer Patients.
Shiraishi O; Kato H; Momose K; Hiraki Y; Yasuda A; Shinkai M; Imano M; Yasuda T
Oncology; 2023; 101(3):203-212. PubMed ID: 36599320
[TBL] [Abstract][Full Text] [Related]
10. Implication of changes in PD-L1 expression during neoadjuvant chemotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF) regimen in esophageal squamous cell carcinoma.
Mitani S; Kawakami H; Shiraishi O; Kanemura H; Suzuki S; Haratani K; Hayashi H; Yonesaka K; Chiba Y; Yasuda T; Nakagawa K
Esophagus; 2023 Apr; 20(2):281-289. PubMed ID: 36484900
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant Triplet Chemotherapy with Docetaxel, Cisplatin plus 5-Fluorouracil versus Docetaxel, Cisplatin plus S-1 for Advanced Esophageal Squamous cell Carcinoma: Propensity Score Matched Analysis.
Kitadani J; Ojima T; Hayata K; Goda T; Takeuchi A; Tominaga S; Fukuda N; Nakai T; Yamaue H; Kawai M
Oncology; 2024; 102(3):228-238. PubMed ID: 37708864
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant chemotherapy for locally advanced esophageal cancer comparing cisplatin and 5-fluorouracil versus docetaxel plus cisplatin and 5-fluorouracil: a propensity score matching analysis.
Nishiwaki N; Noma K; Kunitomo T; Hashimoto M; Maeda N; Tanabe S; Sakurama K; Shirakawa Y; Fujiwara T
Esophagus; 2022 Oct; 19(4):626-638. PubMed ID: 35792947
[TBL] [Abstract][Full Text] [Related]
13. Impact of docetaxel in addition to cisplatin and fluorouracil as neoadjuvant treatment for resectable stage III or T3 esophageal cancer: a propensity score-matched analysis.
Nomura M; Oze I; Abe T; Komori A; Narita Y; Masuishi T; Taniguchi H; Kadowaki S; Ura T; Andoh M; Kawai R; Uemura N; Ishihara M; Tanaka T; Tajika M; Niwa Y; Muro K; Muto M
Cancer Chemother Pharmacol; 2015 Aug; 76(2):357-63. PubMed ID: 26092324
[TBL] [Abstract][Full Text] [Related]
14. Tumor-infiltrating lymphocytes in patients undergoing esophagectomy following neoadjuvant DCF therapy.
Takahashi K; Sakashita Y; Murahashi M; Kubota H; Shimoda M; Ishikawa Y; Tanishima Y; Kurogochi T; Yano F; Eto K
J Surg Oncol; 2024 Mar; 129(4):700-707. PubMed ID: 38031881
[TBL] [Abstract][Full Text] [Related]
15. Docetaxel+Cisplatin+5-FU (DCF) Therapy as a Preoperative Chemotherapy to Advanced Esophageal Squamous Cell Carcinoma: A Single-center Retrospective Cohort Study.
Umeki Y; Matsuoka H; Fujita M; Goto A; Serizawa A; Nakamura K; Akimoto S; Nakauchi M; Tanaka T; Shibasaki S; Inaba K; Uyama I; Suda K
Intern Med; 2023; 62(3):319-325. PubMed ID: 36725064
[TBL] [Abstract][Full Text] [Related]
16. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
17. Impact of CT-assessed changes in tumor size after neoadjuvant chemotherapy on pathological response and survival of patients with esophageal squamous cell carcinoma.
Matsumoto S; Wakatsuki K; Nakade H; Kunishige T; Miyao S; Tsujimoto A; Tatsumi T; Sho M
Langenbecks Arch Surg; 2022 May; 407(3):965-974. PubMed ID: 34989856
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of the prognostic nutritional index in esophageal cancer patients undergoing neoadjuvant chemotherapy.
Nakatani M; Migita K; Matsumoto S; Wakatsuki K; Ito M; Nakade H; Kunishige T; Kitano M; Kanehiro H
Dis Esophagus; 2017 Aug; 30(8):1-7. PubMed ID: 28575242
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
20. Total Lesion Glycolysis Ratio in Positron Emission Tomography/Computed Tomography Images During Neoadjuvant Chemotherapy Can Predict Pathological Tumor Regression Grade and Prognosis in Patients with Locally Advanced Squamous Cell Carcinoma of the Esophagus.
Sonoda A; Yoshida N; Shiraishi S; Horinouchi T; Tokunaga R; Harada K; Iwatsuki M; Nagai Y; Baba Y; Iwagami S; Miyamoto Y; Baba H
Ann Surg Oncol; 2021 Jan; 28(1):167-174. PubMed ID: 32588261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
